To become a global leader in the vaccine industry and offer vaccine solutions for unmet public health needs
Working to solve the world's infectious disease threats by combining rational antigen design and protein engineering to create virus-like particle vaccines
Dr. Jiang Zhu started his lab at The Scripps Research Institute (TSRI) working on antibody discovery and rational vaccine design.
Uvax Bio was founded, utilizing proprietary 1c-SApNP® platform technology developed by Dr. Jiang Zhu.
1c-SApNP® vaccine construct design was finalized for HIV-1. High-yield research cell bank (RCB) development started.
HIV-1 vaccine candidates in preparation for Phase 1 trials. Three new vaccine assets currently in RCB development.
HIV-1 Preclinical data published. The National Institutes of Health (NIH) has agreed to sponsor a Phase 1 clinical trial.